Literature DB >> 26052379

Liver steatosis in hepatitis C patients.

Emilio González-Reimers1, Geraldine Quintero-Platt1, Melchor Rodríguez-Gaspar1, Remedios Alemán-Valls1, Onán Pérez-Hernández1, Francisco Santolaria-Fernández1.   

Abstract

There is controversy regarding some aspects of hepatitis C virus (HCV) infection-associated liver steatosis, and their relationship with body fat stores. It has classically been found that HCV, especially genotype 3, exerts direct metabolic effects which lead to liver steatosis. This supports the existence of a so called viral steatosis and a metabolic steatosis, which would affect HCV patients who are also obese or diabetics. In fact, several genotypes exert metabolic effects which overlap with some of those observed in the metabolic syndrome. In this review we will analyse the pathogenic pathways involved in the development of steatosis in HCV patients. Several cytokines and adipokines also become activated and are involved in "pure" steatosic effects, in addition to inflammation. They are probably responsible for the evolution of simple steatosis to steatohepatitis, making it difficult to explain why such alterations only affect a proportion of steatosic patients.

Entities:  

Keywords:  Fatty acid oxidation; Hepatitis C virus steatosis adiponectin; Insulin resistance; Leptin; Proinflammatory cytokines; Triglyceride synthesis

Year:  2015        PMID: 26052379      PMCID: PMC4450197          DOI: 10.4254/wjh.v7.i10.1337

Source DB:  PubMed          Journal:  World J Hepatol


  105 in total

1.  Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C.

Authors:  Elena Lima-Cabello; María Victoria García-Mediavilla; María E Miquilena-Colina; Javier Vargas-Castrillón; Tamara Lozano-Rodríguez; Miguel Fernández-Bermejo; José Luis Olcoz; Javier González-Gallego; Carmelo García-Monzón; Sonia Sánchez-Campos
Journal:  Clin Sci (Lond)       Date:  2011-03       Impact factor: 6.124

2.  Temporal pattern of de novo lipogenesis in the postprandial state in healthy men.

Authors:  Maureen T Timlin; Elizabeth J Parks
Journal:  Am J Clin Nutr       Date:  2005-01       Impact factor: 7.045

3.  PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes.

Authors:  Susan E Schadinger; Nancy L R Bucher; Barbara M Schreiber; Stephen R Farmer
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-01-11       Impact factor: 4.310

4.  Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis.

Authors:  Donna L White; Vlad Ratziu; Hashem B El-Serag
Journal:  J Hepatol       Date:  2008-08-21       Impact factor: 25.083

5.  Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis.

Authors:  Arzu Tiftikci; Ozlen Atug; Yusuf Yilmaz; Fatih Eren; Filiz Ture Ozdemir; Suna Yapali; Osman Ozdogan; Cigdem Ataizi Celikel; Nese Imeryuz; Nurdan Tozun
Journal:  Arch Med Res       Date:  2009-05       Impact factor: 2.235

6.  SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase.

Authors:  Xiuyun Hou; Shanqin Xu; Karlene A Maitland-Toolan; Kaori Sato; Bingbing Jiang; Yasuo Ido; Fan Lan; Kenneth Walsh; Michel Wierzbicki; Tony J Verbeuren; Richard A Cohen; Mengwei Zang
Journal:  J Biol Chem       Date:  2008-05-14       Impact factor: 5.157

7.  Forkhead box transcription factor regulation and lipid accumulation by hepatitis C virus.

Authors:  Sandip K Bose; Hangeun Kim; Keith Meyer; Nathan Wolins; Nicholas O Davidson; Ranjit Ray
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

8.  Association between leptin, metabolic factors and liver histology in patients with chronic hepatitis C.

Authors:  Robert P Myers; Djamila Messous; Thierry Poynard; Francoise Imbert-Bismut
Journal:  Can J Gastroenterol       Date:  2007-05       Impact factor: 3.522

Review 9.  Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia.

Authors:  Janet D Sparks; Charles E Sparks; Khosrow Adeli
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-07-12       Impact factor: 8.311

10.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.

Authors:  T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki
Journal:  Nat Med       Date:  2002-10-07       Impact factor: 53.440

View more
  5 in total

Review 1.  Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.

Authors:  Yuki Haga; Tatsuo Kanda; Reina Sasaki; Masato Nakamura; Shingo Nakamoto; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2015-12-14       Impact factor: 5.742

2.  The expression of thymosin β4 in chronic hepatitis B combined nonalcoholic fatty liver disease.

Authors:  Jing Liang; Wenjuan Cai; Tao Han; Li Jing; Zhe Ma; Yingtang Gao
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

3.  Target delivery of small interfering RNAs with vitamin E-coupled nanoparticles for treating hepatitis C.

Authors:  Liang Duan; Yan Yan; Jingyi Liu; Bo Wang; Pu Li; Qin Hu; Weixian Chen
Journal:  Sci Rep       Date:  2016-04-26       Impact factor: 4.379

4.  Direct-acting antiviral agents against hepatitis C virus and lipid metabolism.

Authors:  Tatsuo Kanda; Mitsuhiko Moriyama
Journal:  World J Gastroenterol       Date:  2017-08-21       Impact factor: 5.742

5.  CD2-Associated Protein Contributes to Hepatitis C, Virus Propagation and Steatosis by Disrupting Insulin Signaling.

Authors:  Huixia Zhang; Chao Zhang; Hong Tang; Shanshan Gao; Fang Sun; Yuan Yang; Weiping Zhou; Yu Hu; Changshu Ke; Yu Wu; Zeyang Ding; Lin Guo; Rongjuan Pei; Xinwen Chen; Man-Sun Sy; Bixiang Zhang; Chaoyang Li
Journal:  Hepatology       Date:  2018-11       Impact factor: 17.425

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.